The German Cancer Research Center is now initiating a clinical trial for AML, combining allogeneic NK cell therapy with the PARP1 inhibitor talazoparib to induce re-expression of NKG2D ligands on tumor cells [clinicaltrials.gov ID: NCT05319249]. The gene discussed is KLRK1; the disease is cancer.